Fresenius SE & Co. KGaA (FRA:FRE) Given a €33.00 Price Target at Barclays

Barclays set a €33.00 ($33.67) price objective on Fresenius SE & Co. KGaA (FRA:FREGet Rating) in a report released on Tuesday morning, Borsen Zeitung reports.

FRE has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft set a €25.00 ($25.51) target price on Fresenius SE & Co. KGaA in a research report on Tuesday, November 1st. Berenberg Bank set a €46.10 ($47.04) price target on Fresenius SE & Co. KGaA in a report on Wednesday, October 26th. Warburg Research set a €34.00 ($34.69) price target on Fresenius SE & Co. KGaA in a report on Tuesday, November 1st. Morgan Stanley set a €28.00 ($28.57) target price on Fresenius SE & Co. KGaA in a report on Tuesday, October 18th. Finally, Credit Suisse Group set a €24.00 ($24.49) price target on Fresenius SE & Co. KGaA in a research note on Wednesday, November 9th.

Fresenius SE & Co. KGaA Price Performance

FRE opened at €24.68 ($25.18) on Tuesday. The business has a fifty day moving average price of €22.67 and a 200 day moving average price of €26.22. Fresenius SE & Co. KGaA has a 12 month low of €60.16 ($61.39) and a 12 month high of €80.00 ($81.63).

Fresenius SE & Co. KGaA Company Profile

(Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Further Reading

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.